Breaking News
Get 55% Off 0
Get Premium Data for Cyber Monday: Up to 55% Off InvestingPro
CLAIM SALE
Close

Hansa Biopharma AB (HNSAs)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
38.37 0.00    0.00%
28/10 - Closed. Currency in SEK
Type:  Equity
Market:  Euro Zone
ISIN:  SE0002148817 
  • Volume: 0
  • Bid/Ask: 41.66 / 46.84
  • Day's Range: 38.37 - 38.37
Hansa Biopharma 38.37 0.00 0.00%

Hansa Biopharma AB Company Profile

 
Get an in-depth profile of Hansa Biopharma AB, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

168

Equity Type

ORD

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States.The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Contact Information

Address ScheelevAegen 22
Lund, 223 63
Sweden
Phone 46 46 16 56 70
Fax -

Top Executives

Name Age Since Title
Gunnar Tufveson - - Chairman of European Medical Advisory Board in Transplantation
Stanley Jordan - - Chairman of US Medical Advisory Board in Transplantation
Peter Nicklin 60 2022 Independent Chairman of the Board
Christophe Legendre - - Member of European Medical Advisory Board in Transplantation
Kathryn Wood - - Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation
Robert A. Montgomery - - Member of US Medical Advisory Board in Transplantation
Anders Gersel Pedersen 73 2018 Independent Director
Eva Nilsagard 60 2019 Independent Director
Mats Peter Blom 59 2019 Independent Director
Hilary M. Malone 59 2021 Independent Director
Florian Nicolas Christian Reinaud 51 2024 Director
Jonas Wikstrom - 2024 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HNSA Comments

Write your thoughts about Hansa Biopharma AB
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
lau panduro
lau panduro Apr 02, 2024 8:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
think it's time to buy ... 2 strong quarter 💪
BumHunters Archer
JohnJenga Sep 06, 2021 6:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1630923594_18712.jpg
Run baby
Peter Hovgaard
Peter Hovgaard Sep 03, 2020 2:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.redeye.se/research/792767/hansa-biopharma-plattformspotential-driver-upp-vardering?utm_source=avanza&utm_medium=RSS
Peter Hovgaard
Peter Hovgaard Aug 26, 2020 2:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://news.cision.com/hansa-biopharma-ab/r/the-eu-commission-grants-conditional-approval-for-idefirix-tm---imlifidase--in-highly-sensitized-kid,c3181977
Peter Hovgaard
Peter Hovgaard Aug 14, 2020 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://streamio.com/api/v1/videos/5f3512566f8d8dd4d8000001/public_show
Peter Hovgaard
Peter Hovgaard Aug 13, 2020 5:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://cdn.fbsbx.com/v/t59.2708-21/117831693_1914597025350073_1554897188658194790_n.pdf/Intron-Health-Research-Initiation-Hansa-Biopharma-A-Rare-Gem.pdf?_nc_cat=111&_nc_sid=0cab14&_nc_ohc=7LrlyVybJasAX84jF3U&_nc_ht=cdn.fbsbx.com&oh=3f8350d7915c58e168cbd3df20773c00&oe=5F36E9BE&dl=1
Capstar Go
Capstar Go Jun 25, 2020 5:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Press releases & NewsHansa Biopharma receives positive CHMP opinion for Idefirix[TM] (imlifidase) for kidney transplant in EU
Capstar Go
Capstar Go Jun 25, 2020 4:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CHMP recommendations approved
Harri Rautiainen
Harri Rautiainen Jun 11, 2018 5:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
152871054577145.jpg
Short-term dipping, in loger run a promising share.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email